NASDAQ:MLNT - Melinta Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $6.54 +0.29 (+4.64 %) (As of 02/22/2019 04:00 PM ET)Previous Close$6.25Today's Range$4.91 - $6.5452-Week Range$0.64 - $13.80Volume21,241 shsAverage Volume2.23 million shsMarket Capitalization$366.37 millionP/E Ratio-0.30Dividend YieldN/ABeta2.13 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, an antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Vabomere, a carbapenem used in treatment of gram-negative infections; Orbactiv, an antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens, as well as Solithromycin, a macrolide antibiotic for the treatment of CABP. The company also develops Baxdela that in a Phase III clinical trial for treating community-acquired bacterial pneumonia (CABP)); Fusidic Acid, which is in Phase III clinical trial for treating ABSSSIs; and radezolid, a melinta molecule that is in Phase II clinical trial for dermatological applications, as well as ESKAPE pathogen program, which is in preclinical stage targeting superbugs. Melinta Therapeutics, Inc. was formerly known as formerly Rib-X Pharmaceuticals, Inc. and changed its name to Melinta Therapeutics, Inc. in October 2013. The company was founded in 2000 and is headquartered in New Haven, Connecticut. Receive MLNT News and Ratings via Email Sign-up to receive the latest news and ratings for MLNT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:MLNT Previous Symbol CUSIP15130J10 CIK1461993 Webmelinta.com Phone908-617-1309Debt Debt-to-Equity Ratio0.46 Current Ratio1.34 Quick Ratio1.04Price-To-Earnings Trailing P/E Ratio-0.30 Forward P/E Ratio-1.79 P/E GrowthN/A Sales & Book Value Annual Sales$33.86 million Price / Sales10.82 Cash FlowN/A Price / Cash FlowN/A Book Value$2.31 per share Price / Book2.83Profitability EPS (Most Recent Fiscal Year)($21.86) Net Income$-58,910,000.00 Net Margins-202.31% Return on Equity-68.68% Return on Assets-32.84%Miscellaneous Employees300 Outstanding Shares56,020,000Market Cap$366.37 million Next Earnings Date3/12/2019 (Estimated) OptionableOptionable Melinta Therapeutics (NASDAQ:MLNT) Frequently Asked Questions What is Melinta Therapeutics' stock symbol? Melinta Therapeutics trades on the NASDAQ under the ticker symbol "MLNT." When did Melinta Therapeutics' stock split? How did Melinta Therapeutics' stock split work? Shares of Melinta Therapeutics reverse split on Friday, February 22nd 2019. The 1-5 reverse split was announced on Thursday, February 21st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 21st 2019. An investor that had 100 shares of Melinta Therapeutics stock prior to the reverse split would have 20 shares after the split. How were Melinta Therapeutics' earnings last quarter? Melinta Therapeutics Inc (NASDAQ:MLNT) announced its quarterly earnings results on Tuesday, August, 7th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.14) by $0.24. The biotechnology company earned $12.02 million during the quarter, compared to analysts' expectations of $12.06 million. Melinta Therapeutics had a negative return on equity of 68.68% and a negative net margin of 202.31%. View Melinta Therapeutics' Earnings History. When is Melinta Therapeutics' next earnings date? Melinta Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 12th 2019. View Earnings Estimates for Melinta Therapeutics. What price target have analysts set for MLNT? 7 equities research analysts have issued 12 month price objectives for Melinta Therapeutics' shares. Their predictions range from $8.00 to $15.00. On average, they anticipate Melinta Therapeutics' stock price to reach $12.5833 in the next twelve months. This suggests a possible upside of 92.4% from the stock's current price. View Analyst Price Targets for Melinta Therapeutics. What is the consensus analysts' recommendation for Melinta Therapeutics? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Melinta Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Melinta Therapeutics. Has Melinta Therapeutics been receiving favorable news coverage? Media headlines about MLNT stock have trended somewhat positive this week, according to InfoTrie Sentiment. The research firm rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Melinta Therapeutics earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term. Are investors shorting Melinta Therapeutics? Melinta Therapeutics saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 1,178,376 shares, a decrease of 28.3% from the January 15th total of 1,644,462 shares. Based on an average trading volume of 397,029 shares, the short-interest ratio is presently 3.0 days. Currently, 3.3% of the shares of the stock are sold short. View Melinta Therapeutics' Current Options Chain. Who are some of Melinta Therapeutics' key competitors? Some companies that are related to Melinta Therapeutics include Neptune Wellness Solutions (NEPT), Catalyst Pharmaceuticals (CPRX), Kala Pharmaceuticals (KALA), Constellation Pharmaceuticals (CNST), Verrica Pharmaceuticals (VRCA), Emisphere Technologies (EMIS), BIOFRONTERA AG/ADR (BFRA), Immune Design (IMDZ), Kadmon (KDMN), Geron (GERN), TapImmune (MRKR), Aclaris Therapeutics (ACRS), Merus (MRUS), Axsome Therapeutics (AXSM) and Synlogic (SYBX). What other stocks do shareholders of Melinta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Melinta Therapeutics investors own include Gilead Sciences (GILD), Celgene (CELG), Synergy Pharmaceuticals (SGYP), Dynavax Technologies (DVAX), NVIDIA (NVDA), Micron Technology (MU), Portola Pharmaceuticals (PTLA), Novavax (NVAX), ACADIA Pharmaceuticals (ACAD) and TransEnterix (TRXC). Who are Melinta Therapeutics' key executives? Melinta Therapeutics' management team includes the folowing people: Dr. Erin M. Duffy Ph.d., Chief Scientific Officer (Age 51)Mr. John H. Johnson, CEO & Director (Age 61)Dr. Thomas A. Steitz Ph.D., Co-FounderDr. Peter B. Moore Ph.D., Co-FounderDr. William L. Jorgensen Ph.D., Co-Founder Who are Melinta Therapeutics' major shareholders? Melinta Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.52%), First Manhattan Co. (1.69%), Dimensional Fund Advisors LP (1.38%), Millennium Management LLC (1.07%), Fosun International Ltd (0.88%) and Geode Capital Management LLC (0.75%). Company insiders that own Melinta Therapeutics stock include David N Gill, Dov A Md Goldstein, Paul Estrem, Sue Cammarata and Vatera Healthcare Partners Llc. View Institutional Ownership Trends for Melinta Therapeutics. Which institutional investors are selling Melinta Therapeutics stock? MLNT stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co. and Millennium Management LLC. View Insider Buying and Selling for Melinta Therapeutics. Which institutional investors are buying Melinta Therapeutics stock? MLNT stock was acquired by a variety of institutional investors in the last quarter, including Fosun International Ltd, Two Sigma Investments LP, Assenagon Asset Management S.A., Boenning & Scattergood Inc., BlackRock Inc., Condor Capital Management, Dimensional Fund Advisors LP and Rhumbline Advisers. Company insiders that have bought Melinta Therapeutics stock in the last two years include David N Gill, Paul Estrem, Sue Cammarata and Vatera Healthcare Partners Llc. View Insider Buying and Selling for Melinta Therapeutics. How do I buy shares of Melinta Therapeutics? Shares of MLNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Melinta Therapeutics' stock price today? One share of MLNT stock can currently be purchased for approximately $6.54. How big of a company is Melinta Therapeutics? Melinta Therapeutics has a market capitalization of $366.37 million and generates $33.86 million in revenue each year. The biotechnology company earns $-58,910,000.00 in net income (profit) each year or ($21.86) on an earnings per share basis. Melinta Therapeutics employs 300 workers across the globe. What is Melinta Therapeutics' official website? The official website for Melinta Therapeutics is http://melinta.com. How can I contact Melinta Therapeutics? Melinta Therapeutics' mailing address is 300 GEORGE STREET SUITE 301, NEW HAVEN CT, 06511. The biotechnology company can be reached via phone at 908-617-1309 or via email at [email protected] MarketBeat Community Rating for Melinta Therapeutics (NASDAQ MLNT)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 523 (Vote Outperform)Underperform Votes: 385 (Vote Underperform)Total Votes: 908MarketBeat's community ratings are surveys of what our community members think about Melinta Therapeutics and other stocks. Vote "Outperform" if you believe MLNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MLNT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/22/2019 by MarketBeat.com StaffFeatured Article: What is Compound Annual Growth Rate (CAGR)?